We’re delighted to announce that from 1st April 2022, the CRUK Cambridge Centre will become part of a new research network, alongside six other major centres across the UK. Together they will receive £100 million over five years, an investment that will draw together the best research and medical expertise to accelerate advances and transform the outlook for cancer patients.
The Centres in the new network will be Cambridge, City of London, Convergence Science, Manchester, Newcastle, Oxford and Scotland.
Experts at the Cambridge Centre will receive around £22.5 million for their ground-breaking research. The money will be used to accelerate work into diagnosing a wide range of cancers in children and adults at a much earlier stage, including pancreatic, ovarian and children’s cancers.
The funding will support the development of the Centre’s Advanced Imaging capability, enabling scientists to look inside cancer cells in more detail than ever before and find the physical features that could be vulnerable to new treatments.
Professor Richard Gilbertson, Director at the Cancer Research UK Cambridge Centre, said:
“We’ve had a challenging year and COVID-19 has slowed us down. But we will not stop working hard to find new treatments for cancer, and this investment will give us the tools we need to deliver high quality research that will make the biggest difference for patients.
“This investment means we will be able to further develop our work in translational research – getting cutting-edge discoveries from the laboratory to patients and learning as much as possible from patients to initiate new research.”
CRUK awards 'Centre' status to locations that perform the highest quality cancer research. The funding supports essential research infrastructure including technical staff, equipment, pump-priming grants, and training, to further develop the breadth and depth of research at each of these Centres.
The Centres bring together a network of research teams from local universities, NHS hospitals and other research organisations. They seek to understand the impact and efficacy of treatments to initiate new research ideas and programmes, translating cutting-edge discoveries from the laboratory into direct benefits for patients.
Every year around 37,300 people are diagnosed with cancer in the East of England.
Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK, said:
“This past year proves, more than any other, the value of investing in science and medical research, and what can be achieved with collective focus and collaboration. Just like science is our route out of the pandemic, science is our route to beating cancer.
“Despite the impact of the pandemic on the charity’s income, we’re funding some of the best and most promising research in Cambridge to help more people survive.
“Survival rates have doubled since the early 1970s and Cancer Research UK’s work has been at the heart of that progress. Every step our doctors, nurses and scientists take relies on every pound raised through fundraising, and they need support now more than ever.
“Our determination to beat cancer hasn’t faltered and we’re even more focussed on our ambition of seeing three in four people survive their cancer by 2034. One in two of us will get cancer in our lifetimes and all of us can support the research that will beat it.”